Osang’s COVID-19 Self-Test Gets FDA’s Emergency Use Authorization

South Korea-based Osang Healthcare’s OHC COVID-19 antigen self-test has received an Emergency Use Authorization from the FDA.

The over-the-counter home test is authorized for detecting the SARS-CoV-2 coronavirus in individuals with symptoms of COVID-19 within the first seven days of the onset of symptoms or in asymptomatic individuals with reason to suspect they have been exposed to the virus.

The OHC test (the initials stand for the company’s name), which uses nasal swab samples, does not differentiate between the SARS-CoV-2 virus that causes COVID-19 and SARS-CoV, which caused an outbreak of respiratory illness in 2003.